Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2012 Jan 13:12:12.
doi: 10.1186/1471-2407-12-12.

Why do results conflict regarding the prognostic value of the methylation status in colon cancers? The role of the preservation method

Affiliations
Comparative Study

Why do results conflict regarding the prognostic value of the methylation status in colon cancers? The role of the preservation method

Benjamin Tournier et al. BMC Cancer. .

Abstract

Background: In colorectal carcinoma, extensive gene promoter hypermethylation is called the CpG island methylator phenotype (CIMP). Explaining why studies on CIMP and survival yield conflicting results is essential. Most experiments to measure DNA methylation rely on the sodium bisulfite conversion of unmethylated cytosines into uracils. No study has evaluated the performance of bisulfite conversion and methylation levels from matched cryo-preserved and Formalin-Fixed Paraffin Embedded (FFPE) samples using pyrosequencing.

Methods: Couples of matched cryo-preserved and FFPE samples from 40 colon adenocarcinomas were analyzed. Rates of bisulfite conversion and levels of methylation of LINE-1, MLH1 and MGMT markers were measured.

Results: For the reproducibility of bisulfite conversion, the mean of bisulfite-to-bisulfite standard deviation (SD) was 1.3%. The mean of run-to-run SD of PCR/pyrosequencing was 0.9%. Of the 40 DNA couples, only 67.5%, 55.0%, and 57.5% of FFPE DNA were interpretable for LINE-1, MLH1, and MGMT markers, respectively, after the first analysis. On frozen samples the proportion of well converted samples was 95.0%, 97.4% and 87.2% respectively. For DNA showing a total bisulfite conversion, 8 couples (27.6%) for LINE-1, 4 couples (15.4%) for MLH1 and 8 couples (25.8%) for MGMT displayed significant differences in methylation levels.

Conclusions: Frozen samples gave reproducible results for bisulfite conversion and reliable methylation levels. FFPE samples gave unsatisfactory and non reproducible bisulfite conversions leading to random results for methylation levels. The use of FFPE collections to assess DNA methylation by bisulfite methods must not be recommended. This can partly explain the conflicting results on the prognosis of CIMP colon cancers.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic representation of the procedure for evaluating methylation variability, by pyrosequencing, from cryo-preserved tissue DNA. A1, A2, A3 and A4 symbols were the four replicates of the bisulfite conversion A of the pool of tumour DNA performed on day 1, and B1 and B2 the two replicates of the bisulfite conversion B performed on day 2. PCR 1 and 2 were two similar but independent PCRs performed one day apart in duplicate. Pyrosequencing 1 and 2 were two similar but independent pyrosequencing procedures performed one day apart.
Figure 2
Figure 2
Pyrograms of the LINE-1, MLH1 and MGMT methylation markers for different couples of frozen/FFPE DNA. Pyrograms of LINE-1 marker are those obtained for couple n° 10 (A and B) and for MLH1 and MGMT markers those for couples n°13 (C and D) and n°6 (E and F) respectively. Arrows indicate positions of internal controls of conversion, demonstrating no residual cytosines at the non-CpG sites. Gray areas indicate polymorphisms, between T/C, generated by bisulfite treatment. Level of methylation for a given CpG dinucleotide is reported above it (gray square).

Similar articles

Cited by

References

    1. Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358:1148–1159. doi: 10.1056/NEJMra072067. - DOI - PubMed
    1. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer. 2004;4:988–993. doi: 10.1038/nrc1507. - DOI - PubMed
    1. Wong JJ, Hawkins NJ, Ward RL. Colorectal cancer: a model for epigenetic tumorigenesis. Gut. 2007;56:140–148. doi: 10.1136/gut.2005.088799. - DOI - PMC - PubMed
    1. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA. 1999;96:8681–8686. doi: 10.1073/pnas.96.15.8681. - DOI - PMC - PubMed
    1. Barault L, Charon-Barra C, Jooste V, de la Vega MF, Martin L, Roignot P, Rat P, Bouvier AM, Laurent-Puig P, Faivre J. et al.Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res. 2008;68:8541–8546. doi: 10.1158/0008-5472.CAN-08-1171. - DOI - PubMed

Publication types

MeSH terms